- The FDA has granted "breakthrough" status to GlaxoSmithKline's (GSK) Promacta/Revolade (eltrombopag) drug for the treatment of cytopenias in patients with severe aplastic anaemia (SAA) who have had insufficient response to immunosuppressive therapy (IST).
- "SAA is a rare disorder in which the bone marrow fails to make enough new blood cells," GSK says. "Of those patients unresponsive to initial IST, approximately 40% die from infection or bleeding within five years of their diagnosis." Cytopenia is a fall in the number of blood cells. (PR)
- Meanwhile, GSK is set to announce plans to start late-stage trials on ten drugs over the next two years, The Daily Telegraph reports. The testing will include treatments in GSK's key areas of cancer and respiratory disease.
at CNBC.com (Nov 14, 2014)